• Selexis, Pandion Enter Antibody Service Agreement contractpharma
    March 17, 2021
    Selexis SA, a JSR Life Sciences company, has signed a service agreement with Pandion Therapeutics, Inc. to advance the development of Pandion’s PT627, a systemically-acting PD-1 agonist antibody for the potential treatment of autoimmune and ...
PharmaSources Customer Service